EnVVeno Medical Explores Potential Impact of Trump's CVI Diagnosis on Treatment Options

enVVeno Medical Corporation is advancing the VenoValve as a treatment for the estimated 2.5 million Americans affected by severe deep Chronic Venous Insufficiency (CVI). The company's application for FDA approval is anticipated to receive a decision in the second half of 2025. enVVeno recently participated in a Virtual Investor segment, "What This Means," discussing the implications of former President Trump's CVI diagnosis, potentially raising awareness for this condition.

The condition CVI, primarily caused by deep vein thromboses, results in symptoms such as leg swelling and pain. Current treatments do not address deep venous valve dysfunction, which is essential to combat the underlying issue. The expenses associated with this disease burden the U.S. healthcare system significantly, estimated over $26 billion annually.